ClinicalTrials.gg
RecruitingNCT03902444ASSISTENTUpdated Feb 1, 2023

AcandiS Stenting of Intracranial STENosis - regisTry

An observational study in Intracranial Stenosis, sponsored by Acandis GmbH. Recruiting at 16 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by Acandis GmbH · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started May 2016; still recruiting 10 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Constriction, Pathologic with a site in Germany — 6 open to participants now, 8 under way, none of them phase 3. Constriction, Pathologic · Germany.

Planned enrollment
7th of 20
150 · median 122
Started
2016
with 3 others
Observational
20 of 43
5 open now
Registered
28th of 43
by date
Lead sponsor
1 of 43
Acandis GmbH

Among the 43 studies in Constriction, Pathologic with a site in Germany, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 4 that started in 2016, is one of 20 observational ones, and was the 28th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

6 of the 43 studies in Constriction, Pathologic with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Constriction, Pathologic with a site in Germany, or all of them as a file.
02

Study summary

ASSISTENT is designed to collect comprehensive information on technical and clinical safety of the use of Credo® stent together with the NeuroSpeed® PTA balloon catheter in clinical practice in an open registry.

Read the detailed description

ASSISTENT is subdivided into two components. The first part only requires recording of data acquired in routine clinical practice during the treatment of patients with intracranial stenosis with the self-expandable Credo® stent until discharge. This comprises demographic data, data concerning the qualifying clinical event, limited data on medical history and medication, information about the intervention including technical success and periprocedural complications or events, and information about events and clinical status during the in-hospital treatment until hospital discharge.

The second part of the registry consists of a follow-up visit 30 days after the interventional procedure which will be conducted outside of clinical practice.

03

Conditions studied

  • Intracranial Stenosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients over 18 with symptomatic intracranial artery stenosis treated with the self-expandable Credo® stent in the participating sites in clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment with Credo® for symptomatic atherosclerotic intracranial artery stenosis (see product IFU)

Exclusion criteria

Exclusion Criteria:

  • There are no specific exclusion criteria (see product IFU)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Credo® Stent and NeuroSpeed® PTA balloon catheter

    Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine

    Device: Credo® Stent, NeuroSpeed® PTA balloon catheter

Interventions

  • DeviceCredo® Stent, NeuroSpeed® PTA balloon catheter

    a self-expanding stent is used together with a PTA balloon catheter

06

What researchers measure

Primary outcomes

  1. Rate of Technical Success

    • Technical Success

    Time frame: During interventional procedure

  2. Number of Patients with Periprocedural Vascular Events

    * Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA in the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel * Disabling ischemic stroke (MRS 3-6) in the region of the target vessel * TIA outside the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel * Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel

    Time frame: Periprocedural, until 30 days after the interventional procedure

  3. Number of Patients with Cerebrovascular events

    * Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA in the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel * Disabling ischemic stroke (MRS 3-6) in the region of the target vessel * TIA outside the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel * Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel

    Time frame: At hospital discharge - befor the patient leaves the hospital after the intervention; up to 2 weeks, whichever came first

  4. Number of Patients with Cerebrovascular Events

    * Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA * Non-disabling ischemic stroke (MRS 0-2) * Disabling ischemic stroke (MRS 3-6) * Interventional re-treatment of the target vessel

    Time frame: 30 days after the interventional procedure

Secondary outcomes

  1. Number of Patients with Dissection of the target vessel

    Time frame: During interventional procedure

  2. Number of Patients with Occlusion of the target vessel

    Time frame: 30 days after the interventional procedure

  3. Number of Patients with Myocardial infarction

    Time frame: 30 days after the interventional procedure

  4. Number of Patients with Severe extracranial hemorrhage (requiring surgical treatment or transfusion)

    Time frame: 30 days after the interventional procedure

07

Study locations

16 of 16 sites recruiting
  • Universitätsklinikum Knappschaftskrankenhaus Bochum
    Bochum, 44892, Germany
    Recruiting
    • Priv. Doz. Dr. med. Sebastian Fischer · Principal investigator
  • Universitätsklinikum Düsseldorf Institut für Diagnostische und Interventionelle Radiologie Abteilung Neuroradiologie
    Düsseldorf, Germany
    Recruiting
    • Bernd Turowski, Prof. · Contact
  • Alfried Krupp Krankenhaus Essen, Klinik für Neuroradiologie
    Essen, 45131, Germany
    Recruiting
    • Rene Chapot, Prof. · Contact
    • Rene Chapot, Prof · Principal investigator
  • Institut für Diagnostische und Interventionelle Neuroradiologie Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
    Recruiting
    • Christian Riedel, Prof. · Contact
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
    Recruiting
    • Götz Thomalla, MD · Contact
    • Jan Buhk · Principal investigator
  • Asklepios Klinik Altona, Fachbereich Neuroradiologie
    Hamburg, 22769, Germany
    Recruiting
    • Bernd Eckert, Prof · Contact
  • Universitätsklinikum Heidelberg Abteilung für Neuroradiologie
    Heidelberg, 69120, Germany
    Recruiting
    • Markus Möhlenbruch, MD · Contact
  • Universitätsklinikum Homburg
    Homburg, 66424, Germany
    Recruiting
    • Wolfgang Reith, Prof. · Contact
  • Klinikum Ingolstadt
    Ingolstadt, 85049, Germany
    Recruiting
    • Dr. Hendrik Janssen · Principal investigator
  • Uniklinik Köln
    Köln, 50924, Germany
    Recruiting
    • Christoph Kabbasch, MD · Contact
  • Otto-von-Guericke-Universität Magdeburg Universitätsklinik für Neuroradiologie
    Magdeburg, 39120, Germany
    Recruiting
    • Daniel Behme, PD Dr. · Contact
  • Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Diagnostische und Interventionelle Radiologie und Neuroradiologie
    Mönchengladbach, 41063, Germany
    Recruiting
    • Prof. Ringelstein · Contact
  • Evangelisches Krankenhaus Oldenburg; Medizinischer Campus Universität Oldenburg
    Oldenburg, 26122, Germany
    Recruiting
    • Christian Mathys, MD · Contact
  • Klinikum Osnabrück, Klinik für Neurologie
    Osnabrück, 49076, Germany
    Recruiting
    • Lars Krause, MD · Contact
    • Stephan Lowens, MD · Sub investigator
  • KLINIKUM VEST GMBH Knappschaftskrankenhaus Klinik für Radiologie und Neuroradiologie
    Recklinghausen, 45657, Germany
    Recruiting
    • Christian Loehr, Dr. · Contact
  • St. Lukas Klinik GmbH, radprax MVZ GmbH Solingen
    Solingen, 42697, Germany
    Recruiting
    • Hannes Nordmeyer, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2016 (actual). Primary completion is estimated for Mar 2025, 106 months after the start.

Of 64 observational studies under Constriction, Pathologic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 106 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 4, 2019
StartActual
May 2016
Primary completionEst.
Mar 2025
CompletionEst.
Oct 2025
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03902444
Lead sponsor
Acandis GmbH
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
May 2016
Primary completion
Mar 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Feb 1, 2023

Study contacts

Acandis GmbH
Contact
info@acandis.com
+49 723 1155 00
Götz Thomalla, MD
principal investigator · Unversity Medical Center Hamburg-Eppendorf

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion